Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, and Immunogenicity of MB02 vs Avastin in Healthy Males
NCT04238663Phase 1Completed
- Sponsor
- mAbxience
- Start
- Sep 2019
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bevacizumab MB02 in colorectal cancer (metastatic) (mCRC), Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), glioblastoma (GBM) and 3 more (3 arms), sponsored by mAbxience. Primary endpoints: Maximum Observed Serum Concentration at Day 100 and Area Under the Serum Concentration-time Curve From Time Zero to Infinity at Day 100. Started Sep 2019; status: completed.
02
Drugs
bevacizumab MB02
03
Conditions
colorectal cancer (metastatic) (mCRC)Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)glioblastoma (GBM)metastatic renal cell carcinoma (mRCC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04238663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04238663.